This finding indicates that immune-activated cells, such as CD8 T cells [24], were significantly richer in low-risk group, which can effectively recognize antigens to kill tumor cells and enhance the effect of ICI immunotherapy. The gene discussed is CD8A; the disease is neoplasm.